Targeting B-cell maturation antigen (BCMA) with GSK2857916 antibody-drug conjugate provides durable responses in patients (PTS) with heavily-pretreated relapsed/refractory multiple myeloma (RRMM): Preliminary results from study BMA117159

Category Primary study
JournalHaematologica
Year 2018
This article has no abstract
Epistemonikos ID: c3d8c9ab17e2b4c1aa6be3ac2d0d0d728e727b1c
First added on: Feb 09, 2025